Search Page
Save citations to file
Email citations
Email address has not been verified. Go to
My NCBI account settings
to confirm your email and then refresh this page.
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 2021 | 1 |
| 2023 | 1 |
| 2025 | 0 |
Search Results
2 results
Results by year
Filters applied: . Clear all
Page 1
Adjuvant capecitabine versus nihil in older patients with node-positive/high-risk node-negative early breast cancer receiving ibandronate - The ICE randomized clinical trial.
Eur J Cancer. 2023 Nov;194:113324. doi: 10.1016/j.ejca.2023.113324. Epub 2023 Sep 7.
Eur J Cancer. 2023.
PMID: 37797387
Clinical Trial.
Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer.
Hoon SN, Lau PK, White AM, Bulsara MK, Banks PD, Redfern AD.
Hoon SN, et al.
Cochrane Database Syst Rev. 2021 May 26;5(5):CD011220. doi: 10.1002/14651858.CD011220.pub2.
Cochrane Database Syst Rev. 2021.
PMID: 34037241
Free PMC article.
Item in Clipboard
Cite
Cite
ARTICLE TYPE
ARTICLE LANGUAGE
AGE
Filters on the sidebar will be reset to the default list and any currently applied filters will be cleared.